Research School of Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia.
Epidemics. 2022 Sep;40:100591. doi: 10.1016/j.epidem.2022.100591. Epub 2022 Jun 20.
As part of the global effort to eliminate the debilitating mosquito-borne disease lymphatic filariasis (LF), seven rounds of two-drug (diethylcarbamazine and albendazole) mass drug administration (MDA) were conducted in American Samoa over 2000-2006. However subsequent surveys demonstrated ongoing transmission prompting further rounds of three-drug (diethylcarbamazine, albendazole, and ivermectin) MDA starting in 2018.
We extend GEOFIL, a spatially-explicit agent-based model of LF transmission to predict the probability and timing of the local elimination or resurgence of LF for different MDA scenarios starting in 2018: two-drug vs. three-drug MDA, two to seven annual rounds, and population coverage rates of 55-75%. We developed an interactive visualisation comparing the effect of MDA strategies on different outcomes.
At least six annual rounds of three-drug MDA treating 75% of the population were required to achieve LF elimination in American Samoa by 2035 in > 50% of simulations. In scenarios where MDA did not achieve elimination, prevalence doubled approximately every three years, even if MDA reduced antigen prevalence to <1% (the target recommended by the World Health Organisation). Prevalence in six- and seven-year-old children was approximately one quarter of the prevalence in the general population.
The three rounds of three-drug MDA conducted in 2018, 2019, and 2021 may have come close to WHO targets but are unlikely to interrupt LF transmission in American Samoa without further interventions. The recommended post-MDA surveillance strategy of testing primarily six and seven-year-old children will delay detection of resurgence compared to population representative surveys. The recommended elimination targets (reducing antigen prevalence below 0.5%, 1%, or 2%) may not be sufficient to interrupt transmission in countries with LF epidemiology like American Samoa. Alternative surveillance strategies and interventions designed to identify and eliminate spatially localized residual transmission may need to be considered. Interactive visualisations may assist decision-makers to choose locally appropriate strategies.
作为全球消除致残性蚊媒疾病淋巴丝虫病(LF)努力的一部分,2000 年至 2006 年期间,在美属萨摩亚进行了七轮两药(乙胺嗪和阿苯达唑)大规模药物治疗(MDA)。然而,随后的调查表明,传播仍在继续,因此自 2018 年开始进行了三轮三药(乙胺嗪、阿苯达唑和伊维菌素)MDA。
我们扩展了 GEOFIL,这是一种淋巴丝虫病传播的空间明确基于代理的模型,以预测从 2018 年开始不同 MDA 方案下 LF 局部消除或重现的概率和时间:两药与三药 MDA、两到七轮年度 MDA,以及 55-75%的人口覆盖率。我们开发了一个交互式可视化工具,比较 MDA 策略对不同结果的影响。
至少需要进行六轮年度三药 MDA,以在 2035 年前以 50%以上的模拟结果实现美属萨摩亚的 LF 消除。在 MDA 未实现消除的情况下,即使 MDA 将抗原流行率降低到<1%(世界卫生组织推荐的目标),流行率每三年左右也会翻一番。六至七岁儿童的流行率约为一般人群流行率的四分之一。
2018 年、2019 年和 2021 年进行的三轮三药 MDA 可能接近世界卫生组织的目标,但如果没有进一步的干预,不太可能中断美属萨摩亚的 LF 传播。目前推荐的 MDA 后监测策略主要检测六至七岁儿童,与人群代表性调查相比,将延迟对重现的检测。建议的消除目标(将抗原流行率降低到 0.5%、1%或 2%以下)可能不足以中断像美属萨摩亚这样的 LF 流行地区的传播。可能需要考虑设计用于识别和消除空间局部残留传播的替代监测策略和干预措施。交互式可视化工具可能有助于决策者选择适合当地的策略。